Eagle Pharmaceuticals, Inc.

As of August 8, 2023, Eagle Pharmaceuticals, Inc. is considered undervalued with a P/E ratio of 2, a price-to-book value of 0.15, and strong financial metrics, having outperformed the S&P 500 with a year-to-date return of 458%.

As of June 17, 2025, the trend is mildly bullish due to positive weekly MACD and KST indicators, although mixed signals from monthly Bollinger Bands and Dow Theory suggest caution.

As of March 2022, the management team of Eagle Pharmaceuticals, Inc. includes Mr. Michael Graves (Independent Chairman), Mr. Scott Tarriff (CEO and Director), and several Independent Directors: Mr. Richard Edlin, Mr. Robert Glenning, Mr. Steven Ratoff, and Dr. Jennifer Simpson. They oversee the company's operations and strategic direction.

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing injectable products for critical care and oncology. As of June 2023, it reported net sales of $65 million and a net profit of $5 million, with a market cap of $39.78 million.

As of Jun 18, Eagle Pharmaceuticals, Inc. has a market capitalization of 39.78 million, classifying it as a Micro Cap company. For the latest four quarters, it reported net sales of 257.56 million and a net profit of 11.94 million.